Navigation Links
BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
Date:10/28/2008

hts were extended to include Taiwan. In 2007, BioCryst received a $14 million up-front payment and may also receive future clinical event milestone payments (up to $21 million) and commercial event milestone payments (up to $95 million) in addition to double-digit (between 10 percent and 20 percent range) royalty payments on product sales of peramivir. BioCryst retains all rights to commercialize peramivir in North America, Europe and other countries outside of Japan, Taiwan and Korea.

About Peramivir

Peramivir is an antiviral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are resistant to currently available treatments and has been safely administered to healthy subjects at high dose levels. Peramivir is currently being studied in hospitalized and outpatient influenza, utilizing either an intramuscular or intravenous formulation. A Phase 2 trial in outpatient influenza is currently ongoing, a Phase 2 trial in hospitalized influenza was recently completed and BioCryst's partner, Shionogi & Co., Ltd. is preparing for a pivotal Phase 3 trial of peramivir in outpatient influenza.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd., one of Japan's largest research-based pharmaceutical companies develops, manufactures, distributes, imports and exports pharmaceuticals and diagnostics. Shionogi aims to provide innovative medicines which make a positive contribution to world-wide health. For additional company information, please visit Shionogi on the World Wide Web at http://www.shionogi.co.jp.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advanci
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
2. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
3. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
4. LCA-Vision Reports Third Quarter 2008 Financial Results
5. Universal Health Services, Inc. Reports 2008 Third Quarter Results
6. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
7. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
8. WellPoint Reports Third Quarter 2008 Results
9. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
10. Schering-Plough Reports Financial Results for Third Quarter of 2008
11. Quest Diagnostics Reports Growth in Revenue and Earnings for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... measure damaging "brain tsunamis" in injured patients without ... to reality, thanks to pioneering research at the ... research team, led by Jed Hartings, PhD, research ... the UC College of Medicine, has shown that ... brain like tsunami wavescan be measured by the ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
(Date:9/30/2014)... 2014(BRONX, NY)Medications are the leading cause of allergy-related sudden ... death certificates from 1999 to 2010, conducted by researchers ... Albert Einstein College of Medicine of Yeshiva University . ... of Allergy and Clinical Immunology , also found that ... high among older people and African-Americans and that such ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2
... The LFA asks people to join them and show ... FDA-approved medication specifically for lupus , , WASHINGTON, ... Administration (FDA) approved a medication to treat lupus -- when Dwight D. ... effective medications, the Lupus Foundation of America, Inc. (LFA) today launched its ...
... , FLINT, Mich., Sept. 22 Cancer patients residing ... of the most advanced forms of treatment available with a new ... Texas-based health care technology company. , , ... , combines the most advanced treatment capabilities in ...
... , NEW YORK, Sept. 22 Assurant, Inc. ... and insurance-related products and services, will release 2009 third quarter financial results ... will be available on Assurant,s Web site at www.assurant.com ... third quarter conference call at 9:00 a.m. ET on Thursday, Oct. 29, ...
... 22 MedCath Corporation (Nasdaq: MDTH ), a ... diagnosis and treatment of cardiovascular disease, today announced that Art ... Officer effectively immediately. , , Parker ... the company has expanded both the size of its facilities ...
... DENVER, Sept. 22 Anthem Blue Cross and ... has been awarded an Accreditation status of Excellent from the ... that assesses and reports on the quality of the nation,s ... possible level -- is based on a voluntary review of ...
... , , MANHATTAN, Kan., ... Michael Cates, DVM, raised awareness about the One Health Commission at ... Dr. Cates, director of the university,s Master of Public Health Program, ... are very much a "one health" concern. , , ...
Cached Medicine News:Health News:The Lupus Foundation of America, Inc. Asks Supporters to Band Together for Lupus(SM) 2Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 2Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 3Health News:McLaren Health Care Forming Partnership With ProTom International to Build First Proton Beam Therapy Center In Michigan 4Health News:Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29 2Health News:MedCath Names Art Parker Executive Vice President and Chief Financial Officer 2Health News:Anthem Blue Cross and Blue Shield Awarded NCQA's Accreditation Status of 'Excellent' 2Health News:One Health Commission Teaming Up With World Rabies Day to Spread the 'One Health' Message 2
(Date:9/30/2014)... Sept. 30, 2014  Georgia-Pacific Professional is a ... tissue for a wide range of away from ... product lines in healthcare, including hospitals, long-term care ... is introducing its healthcare products and solutions to ... the importance of infection control in the dental ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... (NYSE Amex: NBS ) ("NeoStem" or the ... cell based therapeutics development, today announced two appointments to ... Greenacre, an experienced business leader in the biopharmaceutical industry ... and joins as an additional independent director, and Dr. ...
... YORK, Dec. 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p090656/Global-Gamma/Scintillation-Cameras-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Camera This report ... in US$ Thousand by the following Product ...
Cached Medicine Technology:NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors 2NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors 3NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors 4Global Gamma/Scintillation Cameras Industry 2Global Gamma/Scintillation Cameras Industry 3Global Gamma/Scintillation Cameras Industry 4Global Gamma/Scintillation Cameras Industry 5Global Gamma/Scintillation Cameras Industry 6Global Gamma/Scintillation Cameras Industry 7Global Gamma/Scintillation Cameras Industry 8Global Gamma/Scintillation Cameras Industry 9Global Gamma/Scintillation Cameras Industry 10Global Gamma/Scintillation Cameras Industry 11Global Gamma/Scintillation Cameras Industry 12Global Gamma/Scintillation Cameras Industry 13Global Gamma/Scintillation Cameras Industry 14Global Gamma/Scintillation Cameras Industry 15Global Gamma/Scintillation Cameras Industry 16Global Gamma/Scintillation Cameras Industry 17Global Gamma/Scintillation Cameras Industry 18Global Gamma/Scintillation Cameras Industry 19
... is a suture option for ... diameter looped FiberWire products allow ... extensor tendon repairs while reducing ... passes. FiberLoop is available with ...
... study remains the mainstay in a urologic workup. ... patient needs for an accurate, easy-to-use in-office uroflow ... onset of urine flow and automatically ends when ... urine flow. There is no need to have ...
UroPass Open Tip Ureteral Stents perfect over-the-wire placement with a combination of flexibility and rigidity for comfort and control. When it comes to stent designs, UroPass is a proven leader....
... Ureteral Stents feature teardrop shaped kidney curls ... hydrophilic coating for ease of placement, and ... the trigone. The Multi-Flex advanced design has ... segment provides pushability for placement, and strength ...
Medicine Products: